OncoMatch/Clinical Trials/NCT06752746
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Is NCT06752746 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 9MW3011 for polycythemia vera.
Treatment: 9MW3011 — The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myeloproliferative Neoplasm
Prior therapy
Must have received: hydroxyurea (hydroxyurea) — resistant or intolerant
resistant to or intolerant of hydroxyurea
Must have received: Interferon alpha (Interferon alpha) — resistant or intolerant
resistant to or intolerant of Interferon alpha
Cannot have received: monoclonal antibody
Subjects who have used monoclonal antibodies within the 6 months prior to screening
Cannot have received: antitumor therapeutic drugs for PV
Subjects who have received other antitumor therapeutic drugs for PV prior to screening
Lab requirements
Blood counts
Hematological indicators do not meet the requirements at the time of screening [excluded]
Hematological indicators do not meet the requirements at the time of screening. Abnormal QTc interval of electrocardiogram within the 6 months prior to screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06752746 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior monoclonal antibody, antitumor therapeutic drugs for PV disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages